Certified by Founder
Lodge
smartbax
start up
Germany
- München
- 24/05/2023
- Seed
- $1,291,000
smartbax develops novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms. With the first-in-class compounds, the company targets the multi-drug resistant pathogens methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).
- Industry Biotechnology Research
- Website https://www.smartbax.de/
- LinkedIn https://www.linkedin.com/company/smartbax-gmbh/
Elly | $8,000,000 | (Feb 26, 2026)
Profitmind | $9,000,000 | (Feb 26, 2026)
Abram Scientific | $11,750,000 | (Feb 26, 2026)
Allica Bank | $155,000,000 | (Feb 26, 2026)
Sinergy Flow | $8,273,230 | (Feb 26, 2026)
Quill Meetings | $6,500,000 | (Feb 26, 2026)
Avisi Technologies | $10,700,000 | (Feb 26, 2026)
TBD | $3,000,000 | (Feb 26, 2026)
NationGraph | $18,000,000 | (Feb 26, 2026)
Cicada | $13,500,000 | (Feb 26, 2026)
Koah | $20,500,000 | (Feb 25, 2026)
Nimble | $47,000,000 | (Feb 25, 2026)